Dr Reddy's Laboratories on Thursday said it has inked a pact to acquire Germany-based Nimbus Health GmbH.
The drug major said it has entered into a definitive agreement to acquire the company which is a privately owned, licensed pharmaceutical wholesaler focusing on medical cannabis in Germany.
Dr Reddy's will acquire Nimbus Health for an upfront payment plus performance and milestone-based earn-outs over the next four years, the Hyderabad-based drug maker said in a regulatory filing.
The company however did not share financial details.
The acquisition will allow Dr Reddy's to build on Nimbus Health's strengths and introduce medical cannabis-based medicines as a promising treatment option for patients, it added.
"Medical cannabis is increasingly used to address and treat high unmet medical needs, especially in pain management and CNS. Further, with numerous studies being conducted to leverage and introduce medical cannabis, we believe this is a must-be field for future healthcare delivery," Dr Reddy's Head of European Generics Patrick Aghanian noted.
As more European countries adopt the usage of medical cannabis, the ability to leverage and access newer geographies will be key, he added.
Nimbus Health Founder and Managing Director Linus Maximilian Weber stated that the close alignment between the values of Dr Reddy's and Nimbus gave the company the confidence that the entities can stay focused on the existing business and grow future endeavours together.
Nimbus will operate as a wholly-owned subsidiary of Dr Reddy's, the drug maker stated.
The demand for medical cannabis has increased over the past years with the legalisation of medical cannabis by the German Parliament in 2017.
The medical cannabis market in Germany is already valued at 122 million euros with growth of 25 per cent in 2021 compared to 2020, making Germany one of the largest markets in Europe.
Around 1,50,000 German patients benefit from medical cannabis for their unmet health needs.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)